Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
Thought Leadership, Rare diseases
The impact of real-world data in gaining access to the European orphan drugs market
Thought Leadership, Rare diseases
Navigating early access in Europe: a strategic blueprint for biotech leaders
Blogs, Rare diseases
Early access programs – benefits, challenges and the Sciensus solution
Thought Leadership, Rare diseases
Strategies for entering the European orphan drugs market
Thought Leadership, Rare diseases
Realise your European orphan drug expansion
Thought Leadership, Rare diseases
Take the risk out of your orphan drug distribution in Europe
Thought Leadership, Rare diseases
EU orphan drug roll out: navigating regulatory challenges
Thought Leadership, Rare diseases
Integrating clinical studies and Patient Support Programs(PSPs) for holistic rare disease care